Study to Evaluate the Effectiveness of Legalon®

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

362 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-08

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multinational, multicentre, prospective, non-interventional study (NIS) in non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome treated with Legalon® combined with diet and exercise.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients

NCT02491905

Non-alcoholic Fatty Liver Disease

COMPLETED PHASE2

A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

NCT02285205

Type 2 Diabetes Non-alcoholic Fatty Liver Disease

COMPLETED PHASE4

TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.

NCT03216668

Liver Function Failure

UNKNOWN PHASE3

Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects

NCT05737433

NASH With Fibrosis

COMPLETED EARLY_PHASE1

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

NCT01811472

Non-alcoholic Fatty Liver Disease (NAFLD)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Legalon®

Legalon® 140 mg

Intervention Type DRUG

Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Legalon® 140 mg

Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Legalon® monotherapy prescribed by the treating Investigator according to the SPC, independently from and within a 4-week window prior to enrolment into the study.
2. Male/female, 18 years of age and older
3. Able to provide informed consent
4. Available baseline blood results not older than 4 weeks from inclusion, with elevated plasma level of at least one liver enzyme with respect to normal ranges of local laboratory (\>1 UNL)
5. NAFLD diagnosed by ultrasonography according to the protocol by Hamaguchi or by the protocol of Ballestri
6. Presence of metabolic syndrome, defined as the presence of at least 3 out of 5 of the following:

1. Central obesity (for Asian population, waist circumference ≥90 cm in males, ≥80 cm in females)
2. Insulin resistance (fasting blood glucose ≥100mg/dl or under medication)
3. High blood pressure (≥ 130/85 mmHg or on medication)
4. High triglycerides (≥150 mg/dl or on medication)
5. Low HDL-cholesterol (\<40mg/dl in men, \<50mg/dl in women)
7. Started diet and exercise interventions, as per treating Investigator's suggestion and in line with current guidelines within a 4-week window prior to enrolment into the study

Exclusion Criteria

1. Significant alcohol intake \>7 standard alcoholic drinks per week (70 g ethanol) in women and \>14 (140 g) in men
2. Received Legalon® or any other hepatoprotective treatment before the allowed 4-week window prior to enrolment into the study.
3. On diet and exercise before the allowed 4-week window prior to enrolment into the study.
4. Other concomitant established / diagnosed liver diseases, including chronic hepatitis B, chronic hepatitis C, autoimmune liver diseases (including autoimmune hepatitis), celiac disease, primary biliary cholangitis, primary sclerosing cholangitis, biliary obstruction, drug-induced liver disease (including herbal medicines and dietary supplements), metabolic liver disorders (such as Wilson's disease, alpha-1- antitrypsin deficiency, hemochromatosis, glycogen storage disorders, cholesterol storage disorders), severe liver diseases, non-alcoholic steatohepatitis (NASH) or other forms of advanced fatty liver disease (including clinically relevant fibrosis, \>F2, or established cirrhosis), liver carcinoma
5. Patients treated with drugs with known hepatotoxic effects (at risk of drug-induced liver injury \[DILI\]), including herbal medicines and dietary supplements
6. Other major diseases that, in the treating Investigator opinion, can impair liver function, as for example type 1 diabetes
7. Pregnant and/or breastfeeding women
8. Persons that, in treating Investigator's opinion, are not able to fulfil study requirements
9. Persons that refuses to participate
10. Patients that, in the Investigator's opinion, are or have been infected with COVID-19 (i.e. presence/referral of COVID-19 symptoms or positive antigenic/molecular test)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No